BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

The programme includes the ECLIPSE 1 and ECLIPSE 2 Phase III trials, aiming to offer registrational data for regulatory submissions.

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

YourChoice Therapeutics, Inc., pioneering hormone-free family planning products, announced today that Communications Medicine, a Nature Portfolio journal, has published a peer-reviewed paper on the ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the ...

TRIFOUR is Cantargia's first randomized, controlled study of nadunolimabFirst preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB); ...

R-708-5p is a stress-regulated microRNA and a potential biomarker for the differential diagnosis of human mood disorders.

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...

Nuvectis Pharma, Inc.’s NVCT share price has surged by 12.68%, which has investors questioning if this is right time to sell.

Assembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) was the target of a significant growth in short interest in February. As of February 15th, there was short interest totalling 17,200 shares, ...